DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Has $17.56 Million Stake in CVS Health Co. (NYSE:CVS)

DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lowered its position in CVS Health Co. (NYSE:CVS - Free Report) by 26.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 391,088 shares of the pharmacy operator's stock after selling 141,487 shares during the quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main's holdings in CVS Health were worth $17,556,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Ridgewood Investments LLC increased its stake in shares of CVS Health by 255.7% during the fourth quarter. Ridgewood Investments LLC now owns 626 shares of the pharmacy operator's stock valued at $28,000 after acquiring an additional 450 shares during the period. Stonebridge Financial Group LLC acquired a new position in CVS Health in the 4th quarter worth approximately $28,000. Hopwood Financial Services Inc. acquired a new position in CVS Health in the 4th quarter worth approximately $29,000. Financial Perspectives Inc boosted its stake in CVS Health by 137.5% in the 4th quarter. Financial Perspectives Inc now owns 805 shares of the pharmacy operator's stock worth $36,000 after purchasing an additional 466 shares during the period. Finally, Compass Planning Associates Inc acquired a new position in CVS Health in the 4th quarter worth approximately $37,000. Institutional investors and hedge funds own 80.66% of the company's stock.

Analyst Ratings Changes

A number of research firms recently commented on CVS. Evercore ISI raised their price objective on shares of CVS Health from $60.00 to $65.00 and gave the stock an "outperform" rating in a research note on Monday, January 27th. Morgan Stanley reaffirmed an "overweight" rating on shares of CVS Health in a research note on Tuesday, April 15th. Barclays raised their price objective on shares of CVS Health from $73.00 to $82.00 and gave the stock an "overweight" rating in a research note on Friday, May 2nd. Argus set a $77.00 target price on shares of CVS Health in a research note on Tuesday, February 18th. Finally, Leerink Partners raised shares of CVS Health from a "market perform" rating to an "outperform" rating and lifted their target price for the company from $55.00 to $75.00 in a research note on Thursday, February 13th. Three research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, CVS Health has a consensus rating of "Moderate Buy" and a consensus price target of $74.94.

Insider Activity

In other news, Director Michael F. Mahoney purchased 30,000 shares of CVS Health stock in a transaction on Tuesday, February 18th. The shares were purchased at an average cost of $66.70 per share, for a total transaction of $2,001,000.00. Following the completion of the transaction, the director now directly owns 39,356 shares in the company, valued at approximately $2,625,045.20. This represents a 320.65% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP James David Clark sold 7,513 shares of the business's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total transaction of $498,487.55. Following the completion of the transaction, the senior vice president now owns 8,394 shares in the company, valued at approximately $556,941.90. This trade represents a 47.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.22% of the stock is owned by company insiders.

CVS Health Stock Performance

CVS traded down $2.24 during trading on Monday, hitting $64.74. The stock had a trading volume of 20,508,456 shares, compared to its average volume of 11,448,493. The firm has a market cap of $81.89 billion, a PE ratio of 17.69, a P/E/G ratio of 0.98 and a beta of 0.60. CVS Health Co. has a 12 month low of $43.56 and a 12 month high of $72.51. The company has a current ratio of 0.81, a quick ratio of 0.60 and a debt-to-equity ratio of 0.80. The company has a 50 day simple moving average of $66.96 and a 200-day simple moving average of $59.06.

CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.63. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. The company had revenue of $94.59 billion for the quarter, compared to analyst estimates of $93.07 billion. During the same period last year, the business posted $1.31 EPS. The business's quarterly revenue was up 7.0% on a year-over-year basis. Analysts expect that CVS Health Co. will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd were given a dividend of $0.665 per share. The ex-dividend date of this dividend was Tuesday, April 22nd. This represents a $2.66 annualized dividend and a dividend yield of 4.11%. CVS Health's dividend payout ratio (DPR) is currently 63.48%.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.